Prosecution Insights
Last updated: April 19, 2026

Examiner: BUCKMASTER, MARLENE VRENI

Tech Center 1600 • Art Units: 1671 1672

This examiner grants 27% of resolved cases

Performance Statistics

26.9%
Allow Rate
-33.1% vs TC avg
86
Total Applications
+74.4%
Interview Lift
1384
Avg Prosecution Days
Based on 26 resolved cases, 2023–2026

Rejection Statute Breakdown

5.9%
§101 Eligibility
14.4%
§102 Novelty
33.5%
§103 Obviousness
34.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17835751 SELF-ASSEMBLING VIRAL SPIKE-EABR NANOPARTICLES Final Rejection California Institute of Technology
17925920 CORONAVIRUS ANTIGEN COMPOSITIONS AND THEIR USES Non-Final OA Flagship Pioneering Innovations VI, LLC
17490419 SARS-CoV2 Antigen Lateral Flow Assay Detection Device and Methods of Using the Same Final Rejection Becton, Dickinson and Company
17632733 TRANSPLANT DIAGNOSTICS USING CRISPR-BASED TECHNOLOGY Final Rejection The Brigham and Women's Hospital, Inc.
17457594 METHOD FOR DETECTION OF VIRAL INFECTIONS USING SPLIT ENZYMES Non-Final OA Brigham Young University
18146873 ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF Non-Final OA ACADEMIA SINICA
17696646 METHOD FOR RAPID PREPARATION OF EPIDEMIC INFECTIOUS BRONCHITIS VACCINE Final Rejection SOUTH CHINA AGRICULTURAL UNIVERSITY
17905614 VACCINES AGAINST SARS-COV-2 AND OTHER CORONAVIRUSES Non-Final OA The Government of the United States, as Represented by the Secretary of the Army
17504644 METHOD AND PLATFORM FOR ENHANCING DETECTION ACTIVITY OF INTERACTION BETWEEN SPIKE PROTEIN RECEPTOR BINDING DOMAIN OF CORONAVIRUS FROM SPECIMEN AND HUMAN ANGIOTENSIN-CONVERTING ENZYME II Non-Final OA National Tsing Hua University
18769686 METHODS OF PRODUCING RECOMBINANT ADENOVIRUS VECTORS Final Rejection Ferring International Center S.A.
17906310 PADLOCK PROBE-BASED ROLLING CIRCLE AMPLIFICATION PAIRED WITH NUCLEASE PROTECTION FOR POINT-OF-NEED NUCLEIC ACID DETECTION Final Rejection COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
18015918 A SIMPLE METHOD FOR COLLECTING A SAMPLE OF A MUCOSAL FLUID ADHERED TO THE MUCOSAL SURFACE OF THE NASAL CAVITY AND A TEST KIT FOR DETECTING AN ANALYTE IN THE SAMPLE Non-Final OA Denka Company Limited
17919096 ADENOVIRUS IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT Final Rejection DENKA COMPANY LIMITED
18004964 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ROTAVIRUS Non-Final OA The Wistar Institute of Anatomy and Biology
17493103 FUSION PROTEIN COMPRISING CIRCOVIRIDAE CAPSID PROTEIN, AND CHIMERIC VIRUS-LIKE PARTICLES COMPOSED THEREOF Non-Final OA BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
18008826 POLYPEPTIDE VACCINE COUPLED WITH TLR7 AGONIST FOR NOVEL CORONAVIRUS AND USE THEREOF Non-Final OA SHENZHEN UNIVERSITY
16976277 EXOSOME TARGETING OF CD4+ EXPRESSING CELLS Final Rejection Rhode Island Hospital
18016930 BROADLY NEUTRALIZING BINDING MOLECULES AGAINST MARBURGVIRUSES Non-Final OA La Jolla Institute for Immunology
17997266 METHODS AND KITS FOR DETECTING ADENO-ASSOCIATED VIRUSES Final Rejection LONZA HOUSTON, INC.
18011789 METHOD FOR MASS-PRODUCING VACCINIA VIRUS BY USING SUSPENSION CELLS Final Rejection KOLON LIFE SCIENCE, INC.
18042083 REAGENTS AND METHODS FOR PREVENTING, TREATING OR LIMITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS INFECTION Non-Final OA PHYLEX BIOSCIENCES, INC.
18020210 COMPOSITIONS FOR TREATING GASTROINTESTINAL ADENOCARCINOMAS BY ALTERING THE TUMOR MICROENVIRONMENT Final Rejection Nordic Science Group ApS
18005429 ANTIGENS, ASSAYS, AND METHODS ASSOCIATED WITH SARS-COV-2 Non-Final OA KREUTZ, Fernando Thome
18004148 A DNA PLASMID SARS-CORONA VIRUS-2/COVID-19 VACCINE Non-Final OA STATENS SERUM INSTITUT
17925766 VIRUS STABILIZER, GELATIN HYDROLYSATE FOR VIRUS STABILIZER, AND VIRUS-CONTAINING COMPOSITION Final Rejection INCORPORATED EDUCATIONAL INSTITUTION RAKUNO GAKUEN
17803699 REPLICATION-COMPETENT CONTROLLED HERPESVIRUSES EXPRESSING A SARS COV-2 ANTIGEN Final Rejection HSF Pharmaceuticals SA
17908221 CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST Non-Final OA Dynavax Technologies Corporation
17606614 DOSAGE REGIMENS FOR AND COMPOSITIONS INCLUDING ANTI-RSV ANTIBODIES Final Rejection SANOFI PASTEUR INC.
17784016 INFLUENZA ARRAYS AND USE THEREOF Final Rejection NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
17835235 FLAVIVIRUS ARRAYS AND USE THEREOF Final Rejection NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month